Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: arnold rd. Cancer Chemother Pharmacol. 2009 May;63(6):1035-48. doi: 10.1007/s00280-008-0828-1. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791717 Clinical Trial.
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ. Bulitta JB, et al. Among authors: arnold rd. Cancer Chemother Pharmacol. 2009 May;63(6):1049-63. doi: 10.1007/s00280-008-0827-2. Epub 2008 Sep 13. Cancer Chemother Pharmacol. 2009. PMID: 18791718 Clinical Trial.
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J. O'Connor R, et al. Among authors: arnold rd. Cancer Chemother Pharmacol. 2007 Jan;59(1):79-87. doi: 10.1007/s00280-006-0240-7. Epub 2006 Apr 27. Cancer Chemother Pharmacol. 2007. PMID: 16642371 Clinical Trial.
Phenyl-2-aminoethyl selenide ameliorates hippocampal long-term potentiation and cognitive deficits following doxorubicin treatment.
Alhowail AH, Eggert M, Bloemer J, Pinky PD, Woodie L, Bhattacharya S, Bhattacharya D, Buabeid MA, Smith B, Dhanasekaran M, Piazza G, Reed MN, Escobar M, Arnold RD, Suppiramaniam V. Alhowail AH, et al. Among authors: arnold rd. PLoS One. 2023 Nov 10;18(11):e0294280. doi: 10.1371/journal.pone.0294280. eCollection 2023. PLoS One. 2023. PMID: 37948406 Free PMC article.
Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T, Mazumder S, Davis J, Yadav J, Akinpelu A, Alnaim A, Kumar H, Waliagha R, Church Bird AE, Rais-Bahrami S, Bird RC, Mistriotis P, Mishra A, Yates CC, Mitra AK, Arnold RD. Mitra Ghosh T, et al. Among authors: arnold rd. Cancer Res Commun. 2023 Jul 19;3(7):1286-1311. doi: 10.1158/2767-9764.CRC-22-0427. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37476073 Free PMC article.
89 results